文献速递血脂与心血管预防冠心病

基线低密度脂蛋白胆固醇水平与他汀、依折麦布及PCSK9抑制剂降低LDL-C百分比的关系

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该二次探索性分析基于3项随机安慰剂对照试验(A to Z-TIMI 21、IMPROVE-IT、FOURIER),纳入动脉粥样硬化性心血管疾病患者,评估基线LDL-C水平与药物治疗后LDL-C降低百分比的关系。结果显示,基线LDL-C较低的患者使用PCSK9抑制剂降低百分比更高(70 mg/dL时66.1% vs 130 mg/dL时59.4%),他汀差异较小,依折麦布差异极小;提示即使基线LDL-C较低,强化降脂治疗仍不衰减疗效。

要点

  • PCSK9抑制剂在基线LDL-C较低时降低百分比更高,差异约6.6%。
  • 他汀降低百分比随基线LDL-C降低略有增加,依折麦布差异极小。
  • 即使基线LDL-C较低,强化降脂治疗的百分比降低效应未减弱。

核心结论

  • 他汀、依折麦布和PCSK9抑制剂降低LDL-C的百分比在基线LDL-C较低的患者中并未减弱,且PCSK9抑制剂降低百分比高出6.6%。

研究设计与样本

  • 二次探索性分析,纳入3项随机安慰剂对照试验(A to Z-TIMI 21、IMPROVE-IT、FOURIER)的动脉粥样硬化性心血管疾病患者,分别接受辛伐他汀、依折麦布或evolocumab治疗。
  • 主要分析1个月(A to Z-TIMI 21、IMPROVE-IT)或3个月(FOURIER)时LDL-C降低百分比与基线LDL-C水平的关系,采用广义线性回归模型。

临床怎么用

  • 对于基线LDL-C较低的患者,使用他汀、依折麦布或PCSK9抑制剂仍可获得不衰减的百分比降低,支持强化降脂治疗。
  • PCSK9抑制剂在基线LDL-C较低时降低百分比更高,临床决策时可考虑此特征。

局限性

  • 本研究为二次探索性分析,结果需谨慎解读。
  • 分析仅纳入动脉粥样硬化性心血管疾病患者,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor for atherosclerotic cardiovascular disease. It is unclear whether the percentage LDL-C lowering with pharmacotherapies differs on the basis of baseline LDL-C levels. OBJECTIVE: To evaluate the association between baseline LDL-C levels and the percentage LDL-C reduction with a statin, ezetimibe, and a PCSK9 inhibitor. DESIGN, SETTING, AND PARTICIPANTS: This secondary exploratory study analyzed data from 3 randomized placebo-controlled clinical trials (Aggrastat to Zocor-Thrombolysis in Myocardial Infarction 21 [A to Z-TIMI 21], Improved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT], and Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]) of lipid-lowering therapies (statin, ezetimibe, and a PCSK9 inhibitor) and included participants with atherosclerotic cardiovascular disease. Analyses took place form April to October 2020. INTERVENTIONS: In A to Z-TIMI 21, 1:1 randomization to simvastatin, 40 mg, daily for 30 days followed by 80 mg daily thereafter vs placebo for 4 months followed by simvastatin, 20 mg, daily thereafter. In IMPROVE-IT, 1:1 randomization to ezetimibe, 10 mg, daily plus simvastatin, 40 mg, daily vs placebo plus simvastatin, 40 mg, daily. In FOURIER, 1:1 randomization to evolocumab, 140 mg, every 2 weeks or 420 mg monthly vs matching placebo. MAIN OUTCOMES AND MEASURES: The percentage LDL-C reduction at either 1 month (A to Z-TIMI 21, IMPROVE-IT) or 3 months (FOURIER) as a function of baseline LDL-C level. Data were modeled using a generalized linear regression model. RESULTS: A total of 3187 patients from A to Z-TIMI 21, 10 680 patients from IMPROVE-IT, and 25 847 patients from FOURIER were analyzed. There was a higher percentage reduction in LDL-C levels with evolocumab in patients with lower baseline LDL-C levels, ranging from 59.4% (95% CI, 59.1%-59.8%) in patients with a baseline LDL-C level of 130 mg/dL to 66.1% (95% CI, 65.6%-66.6%) in patients with a baseline LDL-C level of 70 mg/dL (P < .001). In contrast, across the same range of baseline LDL-C level, there was a more modest difference for simvastatin (44.6% [95% CI, 43.9%-45.2%] vs 47.8% [95% CI, 46.4%-49.2%]; P < .001) and minimal difference with ezetimibe (25.0% [95% CI, 23.3%-26.6%] vs 26.2% [95% CI, 24.2%-28.1%]; P = .007). CONCLUSIONS AND RELEVANCE: The percentage LDL-C reduction with statins, ezetimibe, and PCSK9 inhibition is not attenuated in patients starting with lower baseline LDL-C levels and is 6.6% greater for PCSK9 inhibition. These data are encouraging for the use of intensive LDL-C-lowering therapy even for patients with lower LDL-C levels.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Marcusa DP, Giugliano RP, Park JG, et al. Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2021. PMID: 33185670. doi:10.1001/jamacardio.2020.6184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。